Objective. To determine the time to immediate and sustained clinical improvement in pain and sleep quality with pregabalin in patients with fibromyalgia.
Introduction
Fibromyalgia (FM) is a chronic pain disorder, defined by the 1990 American College of Rheumatology (ACR) criteria as widespread pain for 3 months and pain at 11 of 18 tender points [1] . Alternative ACR criteria for the clinical diagnosis of FM were developed in 2010 [2] to include a widespread pain index (a measure of the number of painful body regions) and a symptom severity scale, which takes into account the levels of fatigue, sleep disturbance, cognitive symptoms, and other somatic symptoms experienced by the patient.
Patients with FM typically exhibit increased response to normally nonpainful stimuli (allodynia) and heightened sensitivity to painful stimuli, including pressure, heat, and cold (hyperalgesia) [3, 4] . Although widespread chronic pain is the defining criterion for a diagnosis of FM, patients often report a wide range of other symptoms, including stiffness, fatigue, depression, anxiety, and insomnia [5] . Poor sleep quality is common in patients with FM, with sleep difficulties occurring in an estimated 90% of patients [6] . These patients often report difficulty falling asleep, waking several times in the night, and waking feeling unrefreshed [7] .
Pain and sleep have been shown to have a reciprocal relationship in healthy individuals, with pain interfering with sleep and disturbed sleep reducing pain thresholds [8, 9] . This relationship is also seen in patients with FM; sleep disturbances have been shown to play an important role in exacerbating other symptoms of FM, including pain [10] . Pain and poor sleep quality can significantly impact the overall quality of life of patients with FM [11, 12] .
Pregabalin is one of three medications currently approved for the management of FM in the United States [13] . Several short-term, placebo-controlled clinical trials [14] [15] [16] [17] [18] and long-term, placebo-controlled [19] , and open-label [20, 21] studies have shown that treatment with pregabalin results in significant improvements in both pain and sleep in patients with FM. In addition, meta-analyses [22] and systematic reviews [23] have also demonstrated benefits of pregabalin for patients with FM. Improvement in sleep quality with pregabalin in patients with FM has been shown objectively, by polysomnography [24] , and subjectively, by patient-reported outcomes [25] . The effect of pregabalin on pain-related sleep interference has also been documented in other chronic pain conditions [26] ; however, disturbed sleep is not an approved indication for pregabalin.
Although the efficacy of pregabalin has been demonstrated in several clinical trials of FM [14] [15] [16] [17] [18] [19] [20] , little is known about the time course of symptom improvement relative to placebo. More information is available about the onset of efficacy with pregabalin in patients with neuropathic pain (diabetic peripheral neuropathy [DPN] or postherpetic neuralgia [PHN] ). Three studies analyzed the time to improvement in pain with pregabalin compared with placebo [27] [28] [29] . One of these was a large retrospective analysis of daily mean pain scores from nine placebo-controlled trials of pregabalin for neuropathic pain (DPN and PHN). Significant improvement in mean pain scores with pregabalin vs placebo occurred between days 1 and 7 of treatment initiation for patients with DPN and between days 1 and 2 of treatment initiation for patients with PHN [28] . The other two studies used data from individual clinical trials of pregabalin. One study, in patients with DPN or PHN, showed that the time to a reduction of 1 point on the pain numeric rating scale (NRS) was 1 day for the 600 mg/day pregabalin treatment group (at which time the patients were receiving 300 mg/day as part of the dose titration) and 6 days for the flexible dose 150-600 mg/day pregabalin treatment group, and that pain reduction was significant compared with placebo [27] . The other study, in patients with PHN, showed that the median time to improvement in pain relief was 1.5 days for 300 mg/day pregabalin and 3.5 days for 150-600 mg/day pregabalin, and that pain reduction was significant compared with placebo for both treatment arms [29] . Time to improvement in sleep interference with pregabalin has been investigated in a recent analysis of over 4,200 patients with DPN and PHN. This study showed that reduction in mean sleep interference scores occurred within the first 3 days of treatment [30] .
We hypothesized that treatment with pregabalin (150-600 mg/day) might result in a similar time to improvement in pain and sleep quality in patients with FM as has been previously seen for neuropathic pain [28, 30] . We therefore investigated the time to immediate improvement in pain and sleep quality with pregabalin in those treatment arms that were significantly improved at endpoint (by-day analysis of when statistically significant [P < 0.05] improvement first occurs, comparing mean outcome changes with pregabalin vs placebo). As this is a statistical rather than clinical measure of time to improvement with pregabalin, we also investigated the time to onset of sustained clinical improvement in pain and sleep quality with pregabalin in those individual patients who meaningfully responded to pregabalin at endpoint (time to achievement of 1-point improvement on the pain or sleep quality rating scales using standard techniques for time-to-event analysis), as time to onset of sustained clinical improvement with pregabalin is important in the treatment of patients with FM.
Methods

Description of Clinical Trials
Patient data from four similarly designed, parallel-group, 8-to 14-week phase 2 or 3, randomized placebo-controlled trials (RCTs) of pregabalin (150-600 mg/day) for FM [14] [15] [16] [17] were combined for this post hoc analysis (Table 1) . Patients were eligible to participate in a trial if they were aged 18 years with a diagnosis of FM based on the 1990 ACR criteria [1] and had a score of 40 on the visual analog scale (VAS) of the Short-Form McGill Pain Questionnaire at screening and randomization visits. Patients also had to have completed at least four daily pain diaries during the study baseline phase and have an average daily pain score of 4 on an 11-point pain NRS at randomization. In two of the trials [16, 17] , the first week was a singleblind placebo run-in, at the end of which patients who demonstrated a high response to placebo (30% decrease on the pain VAS) were discontinued from the study before randomization. Patients were excluded from Improvement in Pain/Sleep with Pregabalin participating in a trial if they had creatinine clearance 60 mL/min, any inflammatory muscle or other rheumatologic disease, or any other severe pain that could confound assessment or self-evaluation of the pain associated with FM. Patients had to discontinue all medications for pain and sleep disorders prior to starting a trial, although acetaminophen (4 g/day) was permitted as rescue medication for pain and aspirin (325 mg/day) was permitted for myocardial infarct and stroke prophylaxis.
Endpoint mean pain score, derived from patients' daily pain diaries, was either the primary efficacy measure [14] or a co-primary efficacy measure [15] [16] [17] in each clinical trial. In each trial, every morning upon awakening, patients rated their pain over the previous 24 hours on the 11-point pain NRS, where 0 5 no pain and 10 5 worst possible pain [31] . In addition, three trials [15] [16] [17] determined the proportion of patients who achieved a 30% reduction in mean pain score from baseline to endpoint [32] .
Sleep quality was a secondary efficacy parameter in each clinical trial. In each trial, every morning upon awakening, patients rated the quality of their previous night's sleep on an 11-point sleep NRS, where 0 5 best possible sleep and 10 5 worst possible sleep [33] . Although sleep quality was assessed in each trial, patients were not required to have a certain level of sleep disturbance to participate in the trials.
All studies used the Patient Global Impression of Change (PGIC) as either a co-primary [15] [16] [17] or secondary [14] efficacy measure, and three studies used the Fibromyalgia Impact Questionnaire (FIQ) as either a co-primary [15, 16] or secondary [17] efficacy measure. The PGIC is a patient-rated instrument that measures change in the patient's overall status on a scale ranging from 1 (very much improved) to 7 (very much worse) and is based on the validated Clinical Global Impression of Change scale [34] . The FIQ (total score range, 1-100) assesses health status, progress, and outcomes in patients with FM, with higher scores indicating more impairment [35] .
Study medication was administered either twice or three times daily. All patients initially received 150 or 300 mg/ day pregabalin and were titrated up to the randomized dose (150, 300, 450, or 600 mg/day) over a 1-to 2-week period. Across all studies, patients started taking double-blind study medication in the morning after visit 2 (randomization visit).
Analysis of Onset and Maintenance of Response
In this post hoc analysis, the onset of and maintenance of response to pregabalin was analyzed in two ways. Firstly, immediate time to improvement in pain and sleep quality scores (by day, group analysis) was evaluated in the pregabalin treatment arms, which had been shown to have statistically significant improvements in mean pain scores or mean sleep quality scores compared with placebo at endpoint (last observation carried forward [LOCF]). Secondly, Kaplan-Meier analyses were used to estimate the median (or if that did not exist, the 25th quartile) time (in days) to sustained clinical improvement for patients who were classified as responders at trial endpoint on either the pain NRS, sleep NRS, PGIC, or FIQ (those patients with a 30% improvement on the pain NRS, sleep NRS, or FIQ from study baseline to endpoint, or those who were classed as "much improved" or "very much improved" on the PGIC at study endpoint). These definitions, and the methods of analysis given below, were the same as those used in a previous analysis of time to improvement with pregabalin for patients with neuropathic pain [28] .
Time to Immediate Improvement in Pain or Sleep Quality Scores
By-day (group) analyses of the time to immediate improvement in pain and sleep quality were conducted for treatment arms that had a statistically significant improvement with pregabalin vs placebo at endpoint (LOCF). For these treatment arms, differences between the mean pain score and mean sleep quality score for pregabalin vs placebo were calculated on each day up until day 14 (using an analysis of covariance with terms for treatment, center, and baseline as covariates) in order to estimate the time to immediate improvement with pregabalin. Time to immediate improvement in pain and sleep quality was defined as the first of 2 consecutive days for which the mean score on the relevant NRS was statistically significantly (P < 0.05) lower for pregabalin vs placebo. For two of the four studies analyzed herein [16, 17] , this 14-day period constituted the entire dose escalation phase. It is important to note that none of the individual trials were designed to address the time to improvement in clinical endpoints.
Time to Onset of Sustained Clinical Improvements in Pain and Sleep
Study data for each pregabalin dose were pooled for the analysis of time to sustained clinical improvements in pain and sleep in order to increase statistical power. Sustained clinical improvement in pain or sleep quality was defined as a 1-point reduction on the NRS from each individual patient's baseline score. This analysis was carried out only for those patients classified as responders on either the pain NRS, sleep NRS, PGIC, or FIQ (those with a clinically meaningful response to pregabalin).
Pain responders were defined as those patients with 30% improvement on the 11-point pain NRS from study baseline to endpoint. Sleep responders were defined as those patients with 30% improvement on the 11-point sleep quality NRS from study baseline to endpoint. PGIC responders were defined as those patients who classified themselves as "very much improved" or "much improved" on the PGIC scale at study endpoint. FIQ responders were defined as those patients who had a 30% improvement in FIQ total score from study baseline to endpoint. These responder definitions have previously been used in clinical trials of treatments for FM [36] , and the threshold of 30% change in pain scores from baseline has previously been shown to be a minimal clinically relevant response in an FM population [32, 37] . Time to sustained clinical improvement in pain was estimated for pain, sleep, PGIC, and FIQ responders. In addition, time to sustained clinical improvement in sleep was estimated for sleep responders.
Time to onset of sustained clinical improvement was analyzed by using the Kaplan-Meier procedure to estimate the median (or 25th quartile) time in days required to achieve a 1-point reduction on the pain or sleep NRS among responders. Comparisons with placebo were made using the stratified log-rank test.
Results
Patient Disposition and Baseline Characteristics
Across the four studies included in the analysis (Table 1) , there were 12 pregabalin treatment arms comprising 2,069 patients and four placebo arms comprising 689 patients. Baseline patient demographics were similar between groups (Table 2) . Mean (standard deviation) baseline pain and sleep quality scores ranged from 6.8 (1.3) to 7.0 (1.5) and 6.3 (1.7) to 6.4 (1.8) across groups, respectively. Each study showed that pregabalin was generally well tolerated, with most adverse events being of mild or moderate severity [14] [15] [16] [17] and adverse event profiles consistent with that described in the U.S. prescribing information [13] .
Time to Immediate Improvement in Pain and Sleep Quality Scores with Pregabalin
In order to investigate the time to immediate improvement with pregabalin, all 12 pregabalin treatment arms were first analyzed for a significant effect of pregabalin vs placebo on pain and sleep quality at study endpoint (LOCF) ( Table 3 ). Eight of 12 pregabalin treatment arms were associated with a statistically significant (P < 0.05) reduction in pain score vs placebo at study endpoint. Eleven of 12 pregabalin treatment arms were associated with a statistically significant (P < 0.05) reduction in sleep quality scores vs placebo at study endpoint.
Of the eight pregabalin treatment arms that achieved a statistically significant reduction in pain scores at study endpoint (Table 3) , improvements in pain in the by-day analysis occurred at day 1 for seven treatment arms and at day 2 for one treatment arm ( Figure 1A ). The daily dosage when immediate improvement in pain was reached in the by-day analysis was 150 mg/day for seven treatment arms and 300 mg/day for one treatment arm.
Of the 11 pregabalin treatment arms that achieved a statistically significant reduction in sleep quality scores at study endpoint (Table 3) , improvements in sleep quality in the by-day analysis occurred at day 1 for all 11 treatment arms ( Figure 1B) . The daily dosage when immediate improvement in sleep quality was reached in the by-day analysis was 150 mg/day for nine treatment arms and 300 mg/day for two treatment arms.
Time to Onset of Sustained Clinical Improvements in 30% of Responders
Across the four studies, 2,069 patients treated with pregabalin and 689 patients treated with placebo were assessed for responder status on the pain NRS, sleep NRS, and PGIC. For the FIQ, 1,671 patients treated with pregabalin and 558 patients treated with placebo were assessed for responder status, as the Crofford et al. study [14] did not collect FIQ data.
A total of 824 patients (39.8%) receiving pregabalin (150-600 mg/day) and 191 (27.7%) receiving placebo were considered to be pain responders at endpoint (Table 4) . Among pain responders, at least 25% of patients receiving pregabalin achieved a sustained clinical improvement in pain by day 4 compared with day 15 for patients receiving placebo (P < 0.0001) ( Table 4) .
Improvement in Pain/Sleep with Pregabalin
A total of 1,073 patients (51.9%) receiving pregabalin (150-600 mg/day) and 237 (34.4%) receiving placebo were considered to be sleep responders at endpoint (Table 4) . Among sleep responders, 25% of patients receiving pregabalin achieved a sustained clinical improvement in pain by day 3 compared with day 11 for patients receiving placebo (P < 0.0001), and 50% of patients receiving pregabalin achieved a sustained clinical improvement in pain by day 17. The 50th percentile value could not be calculated for placebo, as at no time did 50% of placebo-treated patients achieve a sustained clinical improvement in pain (Table 4) .
A total of 225 patients (39.9%) receiving 600 mg/day pregabalin were considered to be PGIC responders at endpoint, as well as 282 (41.1%) receiving 450 mg/day, 241 (35.1%) receiving 300 mg/day, 40 (30.3%) receiving 150 mg/day, and 183 (26.6%) receiving placebo. Among PGIC responders, at least 25% of patients receiving pregabalin achieved a sustained clinical improvement in pain by day 5 compared with day 22 for patients receiving placebo (P < 0.0001) ( Table 4 ).
A total of 191 patients (33.9%) receiving 600 mg/day pregabalin were considered to be FIQ responders at endpoint, as well as 199 (35.9%) receiving 450 mg/day, 170 (30.8%) receiving 300 mg/day, and 160 (28.7%) receiving placebo. Patients in the Crofford et al. study [14] , which contained the only 150 mg/day pregabalin treatment arm of the four trials analyzed herein, did not complete the FIQ. Among FIQ responders, at least 25% of patients receiving pregabalin achieved a sustained clinical improvement in pain by day 6 compared with day 16 for patients receiving placebo (P 5 0.0230) ( Table 4) .
The time to onset of sustained clinical improvement in sleep quality was also calculated for sleep responders. At least 25% of patients receiving pregabalin achieved a sustained clinical improvement in sleep by day 2 compared with day 9 for patients receiving placebo (P < 0.0001), and at least 50% of patients receiving pregabalin achieved a sustained clinical improvement in sleep by day 11. The 50th percentile value could not be calculated for placebo, as at no time did 50% of placebo-treated patients achieve a sustained clinical improvement in sleep (Table 4) .
Discussion
In order to assess the time to immediate improvement in pain and sleep with pregabalin in patients with FM, this post hoc study analyzed 12 pregabalin treatment arms for significant (P < 0.05 compared with placebo) improvements in pain and sleep quality scores. Eight of these pregabalin treatment arms showed significant improvement in pain at study endpoint vs placebo, and 11 showed significant improvement in sleep quality. In these treatment arms, immediate mean improvements in pain (as assessed in the by-day analysis over the first 14 days of treatment) occurred by day 1 or 2 following treatment initiation, and improvements in sleep occurred by day 1. These results are of potential clinical importance, as they show the rapidity of which treatment with pregabalin could improve mean pain and sleep quality scores in a population of patients with FM. This is the first study to evaluate the time to improvement in either pain or sleep quality in clinical studies of pregabalin for the treatment of FM. Analyses of the time to Crofford et al. [14] Placebo (N 5 Improvement in Pain/Sleep with Pregabalin improvement in pain in response to pregabalin have previously been carried out for patients with neuropathic pain [27] [28] [29] . In these patients, improvement in pain often occurred within 7 days. In addition, the mean time to improvement in daily sleep interference scores in patients with neuropathic pain has been shown to be 1.7 days [30] . The rapid time to improvement in pain and sleep seen in these studies is consistent with the rapid time to improvement in pain and sleep reported in FM patients in the current analysis (1-2 days). However, comparisons between the results of these studies should be made with caution, as they analyzed patients with different types of chronic pain (neuropathic pain vs FM), and the analyses did not always have an identical definition of time to improvement. Additionally, the studies did not always use the same instruments to assess pain and sleep.
In the United States, pregabalin is indicated for use in the treatment of FM pain at a therapeutic dose of 300-450 mg/day, with a starting dose of 150 mg/day [13] . In this analysis, the pregabalin dose when significant improvements in both pain and sleep quality were achieved was 150 mg/day for nine of the 11 treatment arms that achieved significance during the first 14 days of treatment, and 300 mg/day for the other two significant treatment arms, with an average dose of 177 mg/ day when significance was reached. Therefore, the immediate improvements with pregabalin in this analysis were seen during the titration phases of the studies, while patients were taking doses lower than the approved therapeutic doses. This suggests that the benefits of pregabalin in treating FM may be seen even before a patient reaches the optimal treatment dose. However, although the onset of improvement most commonly occurred when patients were taking 150 mg/ day pregabalin, the only 150-mg/day treatment arm in this analysis did not achieve significant reduction in pain severity compared with placebo at study endpoint.
The time to onset of sustained clinical improvement with pregabalin was analyzed by looking at the time (in days) to a 1-point improvement in pain or sleep quality in patients who were classified as 30% responders at study endpoint (LOCF). The time to sustained clinical improvement in pain was achieved significantly faster in pain responders taking pregabalin than in those taking placebo, with 25% of pain responders achieving a sustained clinical improvement in pain by day 4 with pregabalin compared with day 15 for placebo (P < 0.0001). For pregabalin responders, the median time to a sustained clinical improvement in pain was estimated to be 17 days, and the median time to a sustained clinical improvement in sleep was estimated to be 11 days. These median times were not estimable for the placebo groups. Sustained clinical improvements with pregabalin have previously been demonstrated in analyses of time to onset of improvements in pain [28] and sleep interference [30] in patients with neuropathic pain, and the Figure 1 Time to improvement in (A) pain scores and (B) sleep quality scores with pregabalin. *Difference in pain or sleep quality scores for pregabalin vs placebo on the day significant improvement with pregabalin was achieved vs placebo; scores range 0-10.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Table 4 Time to onset of sustained clinical improvements in pain for patients who were pain, sleep, PGIC, or FIQ responders and in sleep quality for patients who were sleep responders * Sustained clinical improvement in pain or sleep quality was defined as a 1-point reduction on the NRS that lasted for 2 consecutive days. Pain and sleep responders were defined as those patients who had a 30% improvement on the 11-point pain or sleep NRS from study baseline to endpoint. PGIC responders were defined as those patients who classified themselves as "very much improved" or "much improved" on the PGIC scale at study endpoint. FIQ responders were defined as those patients who had a 30% improvement in FIQ score from study baseline to endpoint. *Percentile refers to the treatment day at which 25% or 50% of responders achieved a sustained clinical improvement in pain or sleep quality. † Data from Crofford et al. [14] are not included in the FIQ responder analysis, as these data were not collected. Improvement in Pain/Sleep with Pregabalin median time to clinically relevant pain reduction (measured on the FIQ) in a study of pregabalin for FM has been shown to be longer for patients receiving placebo than pregabalin [38] .
This analysis has shown that when pregabalin resulted in a significant improvement in pain or sleep quality compared with placebo at trial endpoint, the effects were generally mediated rapidly (within 1-2 days of commencing treatment). However, the results presented here should be interpreted carefully owing to the limitations of this study.
The by-day (group) analysis of time to immediate improvement looked only at pregabalin treatment arms, where there was a significant improvement vs placebo at study endpoint. The pooled analysis of time to sustained clinical improvement looked at the time to a 1-point improvement in pain or sleep quality NRS scores; however, patients who achieved this did not necessarily maintain the improvement at each study visit until endpoint. The designs of the original RCTs, although similar, were not identical; there were several differences between the first study, which was a phase 2 proof-of-concept study [14] , and the other three, which were phase 3 clinical trials conducted 5-7 years after the first [15] [16] [17] . In addition, two studies [16, 17] excluded placebo responders from the treatment phase of the trials. Not all data used for this analysis were available from each study; for instance, FIQ data were not collected in the earliest study [14] . Sleep quality was only a secondary endpoint in the trials analyzed here, and none of the trials were designed to evaluate the time to improvement in pain or sleep quality. Finally, this analysis did not take into account potential variability within the responder population; individual patient responses to pregabalin could fluctuate during the course of treatment.
Conclusions
In those pregabalin treatment arms that demonstrated significant improvements in pain and sleep at study endpoint compared with placebo, improvements occurred within 1-2 days of initiating treatment. In patients who responded to treatment, sustained clinical improvement in pain and sleep occurred faster with pregabalin than with placebo. These results in patients with FM are similar to those previously seen with pregabalin for the treatment of DPN and PHN [28, 30] .
